BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:40:00 PM | Browse: 416 | Download: 245
Publication Name World Journal of Gastroenterology
Manuscript ID 4027
Country of Manuscript Source South Korea
2013-06-13 12:04
Peer-Review Started
2013-06-14 08:54
To Make the First Decision
2013-06-24 10:28
Return for Revision
2013-07-01 13:28
2013-08-11 16:40
Second Decision
2013-09-17 09:39
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-09-17 11:01
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-11-02 19:59
Typeset the Manuscript
2013-11-26 10:13
Publish the Manuscript Online
2013-12-18 09:53
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Autobiography
Article Title Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir
Manuscript Source Invited Manuscript
All Author List Hana Park, Jun Yong Park, Seung Up Kim, Do Young Kim, Kwang-Hyub Han, Chae Yoon Chon and Sang Hoon Ahn
Funding Agency and Grant Number
Funding Agency Grant Number
Liver Cirrhosis Clinical Research Center, a grant from the Korea Healthcare Technology R and D project, Ministry of Health and Welfare, South Korea HI10C2020
Bilateral International Collaborative R and D Program from the Ministry of Trade, Industry and Energy, South Korea
Corresponding author Sang Hoon Ahn, MD, PhD, Department of Internal Medicine, Yonsei University College of Medicine, 150 Shinchon-dong 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea. ahnsh@yuhs.ac
Keywords Chronic hepatitis B; Antiviral resistance; Suboptimal response; Telbivudine; Lamivudine
Core Tip A suboptimal response is common in patients treated with lamivudine (LAM) + adefovir (ADV) combination therapy and it has also become a new challenge for the management of chronic hepatitis B (CHB) patients. We commenced this study with the effect of telbivudine (LdT) + ADV combination therapy as a rescue therapeutic option in LAM-resistant CHB patients with suboptimal response to LAM + ADV. Our results demonstrated that switching from LAM + ADV to LdT + ADV resulted in superior virologic response, renoprotective effect and similar safety profiles at week 48. These results suggest that LdT + ADV could be a therapeutic option for patients who are unable to use enofovir disoproxil fumarate for any reason.
Publish Date 2013-12-18 09:53
Citation Park H, Park JY, Kim SU, Kim DY, Han KH, Chon CY, Ahn SH. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. World J Gastroenterol 2013; 19(43): 7671-7679
Url http://www.wjgnet.com/1007-9327/full/v19/i43/7671.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i43.7671
Full Article (PDF) WJG-19-7671.pdf
Manuscript File 4027-Review.doc
Answering Reviewers 4027-Answering reviewers.pdf
Copyright License Agreement 4027-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 4027-Language certificate.pdf
Peer-review Report 4027-Peer review(s).pdf
Scientific Editor Work List 4027-Scientific editor work list.doc